Page 2 - Program In Relapsing Multiple Sclerosis Ongoing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EQS-News: Immunic, Inc : Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

EQS-News: Immunic, Inc : Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesEdna kaplanDaniel vittJens kuhleJessica breuNeuroprotective potentialAndreas muehlerPaula schwartzDistribution servicesImmunic incSclerosis centreRx communications groupProgram in relapsing multiple sclerosis ongoingUniversity hospital baselExchange commissionReports positive interim data

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis P.

United statesPaula schwartzEdna kaplanAndreas muehlerJens kuhleJessica breuDaniel vittImmunic incExchange commissionRx communications groupUniversity hospital baselPrnewswire immunic inc nasdaqProgram in relapsing multiple sclerosis ongoingSclerosis centreWeek dataFirst half

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesAndreas muehlerDaniel vittJens kuhleJessica breuEdna kaplanPaula schwartzRx communications groupSclerosis centreUniversity hospital baselPrnewswire immunic inc nasdaqProgram in relapsing multiple sclerosis ongoingExchange commissionImmunic incWeek dataFirst half